Spots Global Cancer Trial Database for advanced prostate cancer
Every month we try and update this database with for advanced prostate cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Whole Body Magnetic Resonance Imaging Study | NCT04117594 | Advanced Prosta... | WB-MRI | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer | NCT02793219 | Prostate Cancer | Sipuleucel-T Docetaxel | 18 Years - | The University of Texas Health Science Center, Houston | |
| Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC | NCT04821622 | Prostate Cancer | talazoparib plu... Placebo plus en... | 18 Years - | Pfizer | |
| Lucrin® Depot Efficacy and Safety Monitoring Study in Patients With Advanced Prostate Cancer and Lower Urinary Tract Symptoms (LUTS) | NCT01078545 | Advanced Prosta... Lower Urinary T... | Leuprolide acet... | 50 Years - | Abbott | |
| Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | NCT05942001 | Advanced Prosta... | HRS-5041 | 18 Years - 80 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Decision Navigation for Advanced Prostate Cancer Treatment Options Using mHealth | NCT03327103 | Decision Suppor... | CHAMPION | 18 Years - | University of Virginia | |
| PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Acetate. | NCT02787837 | Advanced Prosta... Abiraterone ACe... | 18 Years - 99 Years | Centro Nacional de Investigaciones Oncologicas CARLOS III | ||
| Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate | NCT05590793 | Advanced Prosta... Metastatic Pros... Locally Advance... | Triptorelin pam... | 18 Years - | Ipsen | |
| Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA | NCT04319783 | Advanced Prosta... Cancer of Prost... PSA Castrate Resist... | Darolutamide Radiotherapy | 18 Years - | Trans Tasman Radiation Oncology Group | |
| A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity | NCT01262664 | Prostate Cancer | Prohibitin-TP01 | 18 Years - | M.D. Anderson Cancer Center | |
| PRORAD-5 PROstate RADiation in 5 Fractions: Phase Ib Five Fraction Radiotherapy for Patients With Advanced Prostate Cancer | NCT06369246 | Advanced Prosta... | Stereotactic Bo... | 18 Years - | M.D. Anderson Cancer Center | |
| GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer | NCT00089856 | Prostate Cancer | Immunotherapy w... Chemotherapy (T... | 18 Years - | Cell Genesys | |
| A Long-term Observational Study Cohort in Patients With Advanced Prostate Cancer | NCT01383863 | Advanced Prosta... | 18 Years - | Ipsen | ||
| Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists. | NCT02234089 | Advanced Prosta... | Degarelix LHRH agonist (L... | - | Ferring Pharmaceuticals | |
| Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel | NCT02035124 | Advanced Prosta... | BKM 120 Cabazitaxel | 18 Years - | SCRI Development Innovations, LLC | |
| SRAM study_Postate Cancer | NCT03938649 | Advanced Prosta... | Conventional IM... SBRT | 18 Years - | Chinese University of Hong Kong | |
| Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel | NCT02035124 | Advanced Prosta... | BKM 120 Cabazitaxel | 18 Years - | SCRI Development Innovations, LLC | |
| A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer | NCT06095089 | Advanced Prosta... | JNJ-78278343 JNJ-87189401 | 18 Years - | Janssen Research & Development, LLC | |
| Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate | NCT02268175 | Prostate Adenoc... Prostate Cancer High Risk Prost... | Enzalutamide Abiraterone Ace... Prednisone Leuprolide Acet... | 18 Years - | Dana-Farber Cancer Institute | |
| Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer | NCT03511196 | Prostate Cancer Stage IV Prosta... Advanced Prosta... Adenocarcinoma ... | Adaptive Androg... Abiraterone Prednisone | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate | NCT02268175 | Prostate Adenoc... Prostate Cancer High Risk Prost... | Enzalutamide Abiraterone Ace... Prednisone Leuprolide Acet... | 18 Years - | Dana-Farber Cancer Institute | |
| TKI258 in Castrate Resistant Prostate Cancer | NCT00831792 | Prostate Cancer | TK1258 | - | M.D. Anderson Cancer Center | |
| TKI258 in Castrate Resistant Prostate Cancer | NCT00831792 | Prostate Cancer | TK1258 | - | M.D. Anderson Cancer Center | |
| TUPKRP Combined With MAB Therapy for LUTS/PCa | NCT03701659 | Advanced Prosta... Lower Urinary T... Quality of Life Overall Surviva... Progression of ... | Surgery combina... Endocrine thera... | 50 Years - 79 Years | The Third Xiangya Hospital of Central South University | |
| Evaluation of Prostate-Specific Antigen (PSA) Levels in Patients With Advanced Prostate Cancer Treated With Bicalutamide | NCT00871585 | Advanced Prosta... | 40 Years - | AstraZeneca | ||
| Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer | NCT02793219 | Prostate Cancer | Sipuleucel-T Docetaxel | 18 Years - | The University of Texas Health Science Center, Houston | |
| Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer | NCT06006104 | Advanced Prosta... | HRS-4357 inject... | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate | NCT02268175 | Prostate Adenoc... Prostate Cancer High Risk Prost... | Enzalutamide Abiraterone Ace... Prednisone Leuprolide Acet... | 18 Years - | Dana-Farber Cancer Institute | |
| Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists. | NCT02234089 | Advanced Prosta... | Degarelix LHRH agonist (L... | - | Ferring Pharmaceuticals | |
| PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel. | NCT02362620 | Advanced Prosta... Cabazitaxel Docetaxel | 18 Years - 99 Years | Centro Nacional de Investigaciones Oncologicas CARLOS III | ||
| A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer | NCT01306890 | Advanced Prosta... Prostatic Neopl... | sipuleucel-T | 18 Years - | Dendreon | |
| Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer | NCT06006104 | Advanced Prosta... | HRS-4357 inject... | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer | NCT06006104 | Advanced Prosta... | HRS-4357 inject... | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone | NCT00059631 | Prostate Cancer | Mitoxantrone (N... Bortezomib (PS-... | 18 Years - | M.D. Anderson Cancer Center | |
| A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer | NCT05800665 | Advanced Prosta... Metastatic Pros... | RO7656594 | 18 Years - | Genentech, Inc. | |
| Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | NCT05942001 | Advanced Prosta... | HRS-5041 | 18 Years - 80 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer | NCT06095089 | Advanced Prosta... | JNJ-78278343 JNJ-87189401 | 18 Years - | Janssen Research & Development, LLC | |
| A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer | NCT00072670 | Prostate Cancer | Trabectedin | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Phase 1/2 Clinical Study of HRS-4357 in Patients With Advanced Prostate Cancer | NCT06006104 | Advanced Prosta... | HRS-4357 inject... | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| A Long-term Observational Study Cohort in Patients With Advanced Prostate Cancer | NCT01383863 | Advanced Prosta... | 18 Years - | Ipsen | ||
| Technology Based Psychosocial Intervention for Symptom Management and HRQOL in Men Living With Advanced Prostate Cancer | NCT03149185 | Prostate Cancer | Technology base... Technology base... | 50 Years - | Northwestern University | |
| A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity | NCT01262664 | Prostate Cancer | Prohibitin-TP01 | 18 Years - | M.D. Anderson Cancer Center | |
| Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine | NCT00140348 | Prostate Cancer | Immunotherapy a... | 18 Years - | Cell Genesys | |
| SRAM study_Postate Cancer | NCT03938649 | Advanced Prosta... | Conventional IM... SBRT | 18 Years - | Chinese University of Hong Kong | |
| Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer | NCT02494713 | Prostate Cancer | Degarelix Doxorubicin Ketoconazole Docetaxel Estramustine | 18 Years - | The University of Texas Health Science Center, Houston | |
| Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC | NCT04821622 | Prostate Cancer | talazoparib plu... Placebo plus en... | 18 Years - | Pfizer | |
| Decision Navigation for Advanced Prostate Cancer Treatment Options Using mHealth | NCT03327103 | Decision Suppor... | CHAMPION | 18 Years - | University of Virginia | |
| PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel. | NCT02362620 | Advanced Prosta... Cabazitaxel Docetaxel | 18 Years - 99 Years | Centro Nacional de Investigaciones Oncologicas CARLOS III | ||
| ET 743 (Yondelis) in Men With Advanced Prostate Cancer | NCT00147212 | Prostate Cancer | ET 743 | 18 Years - | Massachusetts General Hospital | |
| Whole Body Magnetic Resonance Imaging Study | NCT04117594 | Advanced Prosta... | WB-MRI | 18 Years - | Royal Marsden NHS Foundation Trust | |
| Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | NCT05942001 | Advanced Prosta... | HRS-5041 | 18 Years - 80 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Acetate. | NCT02787837 | Advanced Prosta... Abiraterone ACe... | 18 Years - 99 Years | Centro Nacional de Investigaciones Oncologicas CARLOS III | ||
| Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer | NCT03936218 | Advanced Prosta... | Inj. Goserelin ... Inj. Zoladex (R... | 18 Years - 75 Years | Eurofarma Laboratorios S.A. | |
| Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate Cancer | NCT00140400 | Prostate Cancer | Immunotherapy a... | 18 Years - | Cell Genesys | |
| Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer | NCT02049190 | Prostate Cancer Metastatic Pros... Androgen-indepe... Recurrent Prost... | onapristone abiraterone | 18 Years - | Arno Therapeutics | |
| Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer | NCT03511196 | Prostate Cancer Stage IV Prosta... Advanced Prosta... Adenocarcinoma ... | Adaptive Androg... Abiraterone Prednisone | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Novel Peptide Vaccination for Patients With Advanced Prostate Cancer | NCT01225471 | Prostate Cancer | CDCA1 | 20 Years - 85 Years | Iwate Medical University | |
| Docetaxel Followed by Provenge in Metastatic Prostate Cancer | NCT02793765 | Prostate Cancer | Docetaxel Sipuleucel-T | 18 Years - | The University of Texas Health Science Center, Houston | |
| A Phase 2 Study of Trabectedin (Yondelis) in Adult Male Participants With Advanced Prostate Cancer | NCT00072670 | Prostate Cancer | Trabectedin | 18 Years - | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | |
| Prostate Cancer, Androgen Deprivation Withdrawal and Intermittent Chemotherapy | NCT01224405 | Advanced Prosta... | Docetaxel + LH-... Docetaxel Docetaxel Continuous Doce... Continuous Doce... | 18 Years - | University of Turin, Italy |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
